Contributions of tau-mediated translational dysregulation to pathogenesis and progression of fronto-temporal dementia

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Jose Francisco Abisambra
Organization: UNIVERSITY OF FLORIDA
Fiscal Year: 2024
Award: $566,154
Funding agency: National Institute on Aging

Abstract
 There is a fundamental gap in understanding how mutations on P301 of tau cause memory impairment in
fronto-temporal dementia (FTD). One pathological mechanism involves the association of aberrant tau with
ribosomal complexes. However, the consequences of this interaction are unknown. The long-term goal of this
work is to better understand the link between tau P301 mutations and memory impairment in FTD. The objective
of this proposal is to determine the impact of mutant tau on translation. We will use human brain tissues as well
as in vitro and in vivo models to study ribosomes in isolation, translation in cells, and brain pathophysiology in
mice. Our preliminary results substantiate that the association between tau and ribosomal complexes impair
protein synthesis. Therefore, the central hypothesis is that pathological tau inhibits translation of proteins critical
for memory. The rationale for the proposed research is that understanding the tau-mediated mechanism of
ribosomal dysfunction will aid in the design of therapeutic targets for FTD, which currently afflict a vast amount
of individuals. Our strong preliminary data serves as support for testing the hypotheses that 1) pathological tau
engages with different parts of the ribosome, 2) translational repression is present in various in vivo tau
models. and 3) the ribosomes’ affinity for transcripts, capacity, and efficiency are impaired in human FTD
brains. These aims have the potential of extrinsic merit to be used as screening tools for modulators of ribosomal
function. Our approach is innovative because it incorporates novel assays, which offer excellent sensitivity that
is not achievable by more traditional approaches. This work is significant because it departs from the status quo
by testing a new mechanism in which translation dysfunction mediates tauopathic symptoms. This work is
expected to advance the field by filling the gap in understanding of tau-mediated brain dysfunction. This
knowledge will serve to better characterize the link between tau and memory impairment in order to develop
novel therapeutic strategies.

Terms: <AD dementia><Affect><Affinity><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Amentia><Assay><Bioassay><Biological Assay><Brain><Brain Nervous System><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chromosome 17><Cognitive><Complex><Data><Dementia><Development><Disease><Disorder><Dysfunction><Encephalon><Frontal Temporal Dementia><Frontotemporal Dementia><Functional disorder><Future><Genetic><Genetic Alteration><Genetic Change><Genetic defect><Goals><Human><Impairment><In Vitro><Individual><KO mice><Knock-out Mice><Knockout Mice><Knowledge><Link><MT-bound tau><Maps><Measures><Mediating><Memory><Memory Deficit><Memory Loss><Memory impairment><Messenger RNA><Mice><Mice Mammals><Microtubule Stabilization><Mission><Modeling><Modern Man><Molecular><Murine><Mus><Mutation><NIH><National Institutes of Health><Neuronal Dysfunction><Non-Polyadenylated RNA><Null Mouse><Organ><Pathogenesis><Pathologic><Pathology><Persons><Physiologic pulse><Physiopathology><Primary Senile Degenerative Dementia><Protein Biosynthesis><Proteins><Proteomics><Publishing><Pulse><Puromicina><Puromycin><Puromycine><Puromycinum><RNA><RNA Gene Products><RNA-Binding Proteins><Recombinant Proteins><Recombinants><Regulation><Research><Ribonucleic Acid><Ribosomal Interaction><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Ribosomal Proteins><Ribosomes><Risk><Screening procedure><Subcellular Process><Symptoms><Tauopathies><Testing><Transcript><Translating><Translational Inhibition><Translational Repression><Translations><United States National Institutes of Health><Veterans><Work><abnormal brain function><abnormal tau><abnormally aggregated tau protein><aged group><aged groups><aged individual><aged individuals><aged people><aged person><aged persons><aged population><aged populations><aging population><brain dysfunction><brain impairment><brain tissue><common symptom><design><designing><developmental><dysfunctional brain><effective therapy><effective treatment><filamentous tau inclusion><front temporal dementia><frontal lobe dementia><frontotemporal lobar dementia><frontotemporal lobe degeneration associated with dementia><genome mutation><high risk><in vitro Model><in vivo><in vivo Model><innovate><innovation><innovative><mRNA><memory decline><memory dysfunction><microtubule associated protein tau aggregation><microtubule associated protein tau deposit><microtubule associated protein tau mutation><microtubule bound tau><microtubule-associated protein tau mutation><microtubule-bound tau><mouse model><murine model><mutant tau><mutation in microtubule associated protein tau><mutation in microtubule-associated protein tau><neural dysfunction><neuropathologic tau><neuropathological tau><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><overexpress><overexpression><paired helical filament of tau><pathogenic tau><pathogenic tau gene mutation><pathological change in tau><pathophysiology><population aging><primary degenerative dementia><protein synthesis><screening tools><self-aggregate tau><senile dementia of the Alzheimer type><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau PHF><tau Proteins><tau abnormality><tau accumulation><tau aggregate><tau aggregation><tau associated neurodegeneration><tau associated neurodegenerative process><tau expression><tau factor><tau fibrillization><tau filament><tau induced neurodegeneration><tau intronic mutation><tau mediated neurodegeneration><tau mutation><tau neurodegenerative disease><tau neurofibrillary tangle><tau neuropathology><tau oligomer><tau paired helical filament><tau pathological change><tau polymerization><tau-tau interaction><tauopathic neurodegenerative disorder><tauopathy><therapeutic target><trafficking><translation><translation factor><translatome><virtual><τ Proteins><τ aggregation><τ expression><τ mutation>